Breast Cancer: Can We Predict Pathological Complete Response following Neoadjuvant Treatment?

Overview

About this study

This project will investigate whether ctDNA analysis in newly diagnosed stage I, II, III breast cancer patients treated with neoadjuvant systemic therapy can predict pathological Complete Response (pCR).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Inclusion Criteria:

  • Patients eligible for a neoadjuvant approach with either endocrine therapy or chemotherapy:
  • Age >18years old
  • Co-morbidities allow for the treatment of breast cancer with surgery and systemic therapy
  • Stage I, II, or III breast cancer with a minimum tumor size of at least T1c
  • Patient believed to be surgically resectable at completion of neoadjuvant therapy
  • No clinical evidence of metastatic disease

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location Status Contact

Scottsdale/Phoenix, Ariz.

Mayo Clinic principal investigator

Barbara Pockaj, M.D.

Open for enrollment

Contact information:

Regina Becker

(480) 342-6079

Becker.Regina@mayo.edu

More information

Publications

Publications are currently not available

Study Results Summary

Not yet available

Supplemental Study Information

Not yet available

.
CLS-20308371

Mayo Clinic Footer